242 related articles for article (PubMed ID: 18638291)
1. Pharmacokinetics of valacyclovir in the adult horse.
Maxwell LK; Bentz BG; Bourne DW; Erkert RS
J Vet Pharmacol Ther; 2008 Aug; 31(4):312-20. PubMed ID: 18638291
[TBL] [Abstract][Full Text] [Related]
2. Multiple oral dosing of valacyclovir in horses and ponies.
Garré B; Baert K; Nauwynck H; Deprez P; De Backer P; Croubels S
J Vet Pharmacol Ther; 2009 Jun; 32(3):207-12. PubMed ID: 19646083
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses.
Garré B; Shebany K; Gryspeerdt A; Baert K; van der Meulen K; Nauwynck H; Deprez P; De Backer P; Croubels S
Antimicrob Agents Chemother; 2007 Dec; 51(12):4308-14. PubMed ID: 17846132
[TBL] [Abstract][Full Text] [Related]
4. Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilitates outpatient treatment.
Hasenburg A; Tong XW; Rojas-Martinez A; Nyberg-Hoffman C; Kieback CC; Kaplan AL; Kaufman RH; Ramzy I; Aguilar-Cordova E; Kieback DG
Anticancer Res; 1999; 19(3B):2163-5. PubMed ID: 10472325
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of acyclovir in the cat.
Owens JG; Nasisse MP; Tadepalli SM; Dorman DC
J Vet Pharmacol Ther; 1996 Dec; 19(6):488-90. PubMed ID: 8971679
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism.
Anand BS; Katragadda S; Mitra AK
J Pharmacol Exp Ther; 2004 Nov; 311(2):659-67. PubMed ID: 15226381
[TBL] [Abstract][Full Text] [Related]
7. Vitreous penetration of orally administered valacyclovir.
Huynh TH; Johnson MW; Comer GM; Fish DN
Am J Ophthalmol; 2008 Apr; 145(4):682-6. PubMed ID: 18226802
[TBL] [Abstract][Full Text] [Related]
8. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children.
Nadal D; Leverger G; Sokal EM; Floret D; Perel Y; Leibundgut K; Weller S
J Infect Dis; 2002 Oct; 186 Suppl 1():S123-30. PubMed ID: 12353197
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age.
Kimberlin DW; Jacobs RF; Weller S; van der Walt JS; Heitman CK; Man CY; Bradley JS
Clin Infect Dis; 2010 Jan; 50(2):221-8. PubMed ID: 20014952
[TBL] [Abstract][Full Text] [Related]
10. Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection.
Bras AP; Sitar DS; Aoki FY
Can J Clin Pharmacol; 2001; 8(4):207-11. PubMed ID: 11743593
[TBL] [Abstract][Full Text] [Related]
11. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys.
de Miranda P; Burnette TC
Drug Metab Dispos; 1994; 22(1):55-9. PubMed ID: 8149890
[TBL] [Abstract][Full Text] [Related]
12. Effects of anti herpetic drugs on mice with herpetic epithelial keratitis after reactivation of herpes simplex virus type 1.
Itahashi M; Higaki S; Shimomura Y
Semin Ophthalmol; 2008; 23(4):241-7. PubMed ID: 18584562
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness.
Simon MW; Fish DN; Deeter RG
Drugs R D; 2002; 3(6):365-73. PubMed ID: 12516939
[TBL] [Abstract][Full Text] [Related]
14. Topical iontophoresis of valaciclovir hydrochloride improves cutaneous aciclovir delivery.
Abla N; Naik A; Guy RH; Kalia YN
Pharm Res; 2006 Aug; 23(8):1842-9. PubMed ID: 16850271
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy.
Eisen D; Essell J; Broun ER; Sigmund D; DeVoe M
Bone Marrow Transplant; 2003 Jan; 31(1):51-5. PubMed ID: 12621507
[TBL] [Abstract][Full Text] [Related]
16. Determination of acyclovir in horse plasma and body fluids by high-performance liquid chromatography combined with fluorescence detection and heated electrospray ionization tandem mass spectrometry.
Maes A; Garré B; Desmet N; van der Meulen K; Nauwynck H; De Backer P; Croubels S
Biomed Chromatogr; 2009 Feb; 23(2):132-40. PubMed ID: 18823074
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function.
Smith JP; Weller S; Johnson B; Nicotera J; Luther JM; Haas DW
Antimicrob Agents Chemother; 2010 Mar; 54(3):1146-51. PubMed ID: 20038622
[TBL] [Abstract][Full Text] [Related]
18. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir.
Lycke J; Malmeström C; Ståhle L
Antimicrob Agents Chemother; 2003 Aug; 47(8):2438-41. PubMed ID: 12878501
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses.
Bentz BG; Maxwell LK; Erkert RS; Royer CM; Davis MS; MacAllister CG; Clarke CR
J Vet Intern Med; 2006; 20(3):589-94. PubMed ID: 16734094
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir?
Eksborg S; Pal N; Kalin M; Palm C; Söderhäll S
Med Pediatr Oncol; 2002 Apr; 38(4):240-6. PubMed ID: 11920787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
